ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bioinformatics"

  • Abstract Number: 1787 • ACR Convergence 2024

    Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis

    Andrea Daamen1, Kathryn Kingsmore2, Prathyusha Bachali3, Nan Shen4, Amrie Grammer5 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Charlottesville, 3AMPEL BioSolutions, Redmond, WA, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), 5AMPEL LLC, Charlottesville, VA

    Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
  • Abstract Number: 2586 • ACR Convergence 2024

    Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis

    Maria Gabriella Raimondo1, Hashem Mohammadian2, Stefano Alivernini3, Simon Rauber1, Filippo Fagni4, Giulia Corte5, Koray Tascilar2, Maria Antonietta D´Agostino6, Georg Schett7, Arnd Kleyer8 and Andreas Ramming1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 3Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, Rome, Italy, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 6Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Charité - Universittsmedizin Berlin, Erlangen, Germany

    Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…
  • Abstract Number: L01 • ACR Convergence 2023

    Analysis of 245,388 Diverse Participants in the NIH All of Us Cohort Identifies VEXAS Resiliency in UBA1 M41L Somatic Mutation Carriers

    Robert Corty1 and Alexander Bick2, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville, TN

    Background/Purpose: VEXAS syndrome is a recently-discovered systemic auto-inflammatory disease caused by somatic mutation at position 41 in the X-linked gene UBA1.1 First, 25 older men…
  • Abstract Number: 0063 • ACR Convergence 2023

    Investigating Macrophage Repopulation in the Synovium

    Jessica Maciuch1, Yidan Wang2, Slim Fourati1, Harris Perlman1 and Deborah Winter3, 1Northwestern University, Chicago, IL, 2Northwestern University, Hanover Park, IL, 3Northwestern University, Skokie, IL

    Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints. Macrophages are a key mediator of pro-inflammatory signaling, contributing to…
  • Abstract Number: 0899 • ACR Convergence 2023

    Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy

    Shudan Wang1, John Greally2, Masako Suzuki3, Jee-Young Moon2, Tao Wang2, Yvonne M Saenger2, Brad Rovin4 and J. Michelle Kahlenberg5, 1Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Texas A&M University, College Station, TX, 4Ohio State University, Columbus, OH, 5University of Michigan, Ann Arbor, MI

    Background/Purpose: Tubulointerstitial injury is a strong predictor of progression to kidney failure in lupus nephritis (LN). Prior animal studies suggest intrarenal complement activation has an…
  • Abstract Number: 1658 • ACR Convergence 2023

    Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis

    Chrissy Bolton1, Christopher Mahony2, Charlotte Smith2, Vicky Alexiou3, Huong Nguyen3, Patricia Reis-Nisa2, Søren Lomholt4, Annie Hackland2, Sugrah Sultan5, Klaudia Kupiec3, Sunit Davda6, Charlene Foley6, Calliope Dendrou1, Elizabeth C Rosser7, Accelerating Medicines Partnership Program RA SLE Network8, Anna Helena Jonsson9, Fan Zhang10, Michael Brenner11, Soumya Raychaudhuri9, Christopher Buckley1, Manigandan Thyagarajan5, Zishan Shiekh5, Sandrine Compeyrot-Lacassagne6, Samantha Chippington6, Mark Coles1, Eslam Al-Abadi5, Andrew Filer2, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium12, Lucy R Wedderburn3 and Adam Croft2, 1University of Oxford, Oxford, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 4Aarhus University, Aarhus, Denmark, 5Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 6Great Ormond Street Hospital, London, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Brigham and Women's Hospital, Boston, MA, 10University of Colorado, Aurora, CO, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 12MRC, Birmingham, United Kingdom

    Background/Purpose: Understanding the unique and shared pathogenic processes between childhood-onset and adult-onset inflammatory arthritides is needed to guide more effective drug development and their application…
  • Abstract Number: 2461 • ACR Convergence 2023

    Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies

    Iago Pinal-Fernandez1, Jose Cesar Milisenda2, Katherine Pak1, Sandra Muñoz-Braceras3, Maria Casal-Dominguez3, Jose Jiram Torres-Ruiz3, Stefania Dell´Orso4, Faiza Naz4, Gustavo Gutierrez-Cruz4, Yaiza Duque-Jaimez2, Ana Matas-Garcia2, Joan Padrosa5, Francesc J Garcia-Garcia2, Mariona Guitart-Manpel2, Gloria Garrabou2, Ernesto Trallero-Araguas6, Brian Wallit7, Julie Paik8, Jemima Albayda8, Lisa Christopher-Stine8, Tom Lloyd9, Josep Maria Grau2, Albert Selva-O’Callaghan6 and Andrew Mammen10, 1National Institutes of Health, Bethesda, MD, 2Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, 3Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5CIBERER, Barcelona, Spain, Barcelona, Spain, 6Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 7National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, 8Johns Hopkins University, Baltimore, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD, 10NIH, Bethesda, MD

    Background/Purpose: Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (AS), and inclusion body myositis (IBM). Myositis-specific autoantibodies…
  • Abstract Number: 0108 • ACR Convergence 2023

    Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database

    Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
  • Abstract Number: 0918 • ACR Convergence 2023

    Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus

    Katie Heitzman1, Sneha Dass1, Linda Hiraki2, Earl Silverman3, Christiaan Scott4, Ana Barrera-Vargas5, Zuoming Deng6, Mariana Kaplan7, Luis Franco8 and Laura Lewandowski9, 1Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Silverman, Toronto, ON, Canada, 4Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 7Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 8Functional Immunogenomics Section, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, 9Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…
  • Abstract Number: 1659 • ACR Convergence 2023

    Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis

    Christopher Mahony1, Chrissy Bolton2, Charlotte Smith1, Vicky Alexiou3, Huong Nguyen3, Patricia Reis-Nisa1, Søren Lomholt4, Annie Hackland1, Sunit Davda5, Sugrah Sultan6, Charlene Foley5, Catherine Cotter6, Klaudia Kupiec3, Calliope Dendrou2, Elizabeth C Rosser7, Accelerating Medicines Partnership (AMP): RA/SLE8, Fan Zhang9, Soumya Raychaudhuri8, Michael Brenner10, Christopher Buckley2, Manigandan Thyagarajan6, Accelerating Medicines Partnership Program RA SLE Network11, Zishan Shiekh6, Sandrine Compeyrot-Lacassagne5, Samantha Chippington5, Mark Coles2, Eslam Al-Abadi6, Andrew Filer1, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium12, Lucy R Wedderburn3 and Adam Croft1, 1University of Birmingham, Birmingham, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 4Aarhus University, Aarhus, Denmark, 5Great Ormond Street Hospital, London, United Kingdom, 6Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 7University College London, London, United Kingdom, 8Brigham and Women's Hospital, Boston, MA, 9University of Colorado, Aurora, CO, 10Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12MRC, Birmingham, United Kingdom

    Background/Purpose: The synovial membrane is the primary target tissue during the effector phase of inflammatory arthritis in children and young people with Juvenile Idiopathic Arthritis…
  • Abstract Number: 2482 • ACR Convergence 2023

    Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis

    Takayuki Fujii1, Dana Orange2, Caryn Hale2, Koichi Murata1, Hideo Onizawa1, Akira Onishi1, Masao Tanaka3, Akio Morinobu4 and Shuichi Matsuda5, 1Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Rockefeller University, New York, NY, 3Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: This study aimed to determine predictors of treatment response and radiographic progression following the initiation of biological disease-modifying antirheumatic medications (bDMARDs) in patients with…
  • Abstract Number: 0131 • ACR Convergence 2023

    Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model

    April Barnado, Ryan Moore, Hank Domenico, Sarah Green, Alex Camai, Ashley Suh, Bryan Han, Katherine Walker, Audrey Anderson, Lannawill Caruth, Anish Katta, Allison McCoy and Daniel W. Byrne, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Up to 20% of the general population has a positive ANA without having autoimmune disease. Currently, no tools exist to help clinicians interpret the…
  • Abstract Number: 0922 • ACR Convergence 2023

    The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles

    Tomás Cerdó1, Carlos Perez-Sanchez2, Laurel Woodridge3, Mª Angeles Aguirre4, Rafaela Ortega Castro5, Ismael Sánchez-Pareja6, Laura Muñoz-Barrera1, Pedro Segui1, Christian Merlo6, Pedro Ortiz Buitrago7, Desiree Ruiz Vilchez8, Maria del Carmen Abalos-Aguilera8, Pilar Font Ugalde1, Nuria Barbarroja9, Alejandro Escudero10, Elizabeth Jury3 and Chary Lopez-Pedrera11, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 2IMIBIC, Córdoba, Spain, 3Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 4Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 5Hospital Reina Sofía, Cordoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 8Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 9University of Cordoba, Córdoba, Spain, 10SAS, Córdoba, Spain, 11IMIBIC - Reina Sofia Hospital, Córdoba, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) poses a significant challenge at the diagnostic and treatment levels due to its severe multisystem nature and notable heterogeneity in…
  • Abstract Number: 1661 • ACR Convergence 2023

    Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin

    Kathryn Torok1, Ying-Ju Lai2, Zhongli Xu3, Anwesha Sanyal3, Giffin Werner3, Theresa Hutchins3, Claire Cheng3 and Wei Chen3, 1University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittbsurgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…
  • Abstract Number: 2515 • ACR Convergence 2023

    Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases

    Shinji Izuka1, Toshihiko Komai1, Takahiro Itamiya1, Mineto Ota2, Saeko Yamada1, Yasuo Nagafuchi2, Hirofumi Shoda1, Kosuke Matsuki3, Kazuhiko Yamamoto4, Tomohisa Okamura5 and Keishi Fujio1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology